One case of massive overdosage has been published. A 79-year-old man attempted suicide by ingesting 13 g of nilutamide (i.e., 43 times the maximum recommended dose). Despite immediate gastric lavage and oral administration of activated charcoal, plasma nilutamide levels peaked at 6 times the normal range 2 hours after ingestion. There were no clinical signs or symptoms or changes in parameters such as transaminases or chest X-ray. Maintenance treatment (150 mg/day) was resumed 30 days later.
In repeated-dose tolerance studies, doses of 600 mg/day and 900 mg/day were administered to 9 and 4 patients, respectively. The ingestion of these doses was associated with gastrointestinal disorders, including nausea and vomiting, malaise, headache, and dizziness. In addition, a transient elevation in hepatic enzyme levels was noted in one patient.
Since nilutamide is protein bound, dialysis may not be useful as treatment for overdose. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken. If vomiting does not occur spontaneously, it should be induced if the patient is alert. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.
Nilutamida Lafedar tablets are contraindicated:
The following adverse experiences were reported during a multicenter clinical trial comparing Nilutamida Lafedar + surgical castration versus placebo + surgical castration. The most frequently reported (greater than 5%) adverse experiences during treatment with Nilutamida Lafedar tablets in combination with surgical castration are listed below. For comparison, adverse experiences seen with surgical castration and placebo are also listed.
| Adverse Experience | Nilutamida Lafedar + surgical castration (N=225) % All | Placebo + surgical castration (N=232) % All |
| Cardiovascular System | ||
| Hypertension | 5.3 | 2.6 |
| Digestive System | ||
| Nausea | 9.8 | 6.0 |
| Constipation | 7.1 | 3.9 |
| Endocrine System | ||
| Hot flushes | 28.4 | 22.4 |
| Metabolic and Nutritional System | ||
| Increased AST | 8.0 | 3.9 |
| Increased ALT | 7.6 | 4.3 |
| Nervous System | ||
| Dizziness | 7.1 | 3.4 |
| Respiratory System | ||
| Dyspnea | 6.2 | 7.3 |
| Special Senses | ||
| Impaired adaptation to dark | 12.9 | 1.3 |
| Abnormal vision | 6.7 | 1.7 |
| Urogenital System | ||
| Urinary tract infection | 8.0 | 9.1 |
The overall incidence of adverse experiences was 86% (194/225) for the Nilutamida Lafedar group and 81% (188/232) for the placebo group.
The following adverse experiences were reported during a multicenter clinical trial comparing Nilutamida Lafedar + leuprolide versus placebo + leuprolide. The most frequently reported (greater than 5%) adverse experiences during treatment with Nilutamida Lafedar tablets in combination with leuprolide are listed below. For comparison, adverse experiences seen with leuprolide and placebo are also listed.
| Adverse Experience | Nilutamida Lafedar +leuprolide (N=209) % All | Placebo +leuprolide (N=202) % All |
| Body as a Whole | ||
| Pain | 26.8 | 27.7 |
| Headache | 13.9 | 10.4 |
| Asthenia | 19.1 | 20.8 |
| Back pain | 11.5 | 16.8 |
| Abdominal pain | 10.0 | 5.4 |
| Chest pain | 7.2 | 4.5 |
| Flu syndrome | 7.2 | 3.0 |
| Fever | 5.3 | 6.4 |
| Cardiovascular System | ||
| Hypertension | 9.1 | 9.9 |
| Digestive System | ||
| Nausea | 23.9 | 8.4 |
| Constipation | 19.6 | 16.8 |
| Anorexia | 11.0 | 6.4 |
| Dyspepsia | 6.7 | 4.5 |
| Vomiting | 5.7 | 4.0 |
| Endocrine System | ||
| Hot flushes | 66.5 | 59.4 |
| Impotence | 11.0 | 12.9 |
| Libido decreased | 11.0 | 4.5 |
| Hemic and Lymphatic System | ||
| Anemia | 7.2 | 6.4 |
| Metabolic and Nutritional System | ||
| Increased AST | 12.9 | 13.9 |
| Peripheral edema | 12.4 | 17.3 |
| Increased ALT | 9.1 | 8.9 |
| Musculoskeletal System | ||
| Bone Pain | 6.2 | 5.0 |
| Nervous System | ||
| Insomnia | 16.3 | 15.8 |
| Dizziness | 10.0 | 11.4 |
| Depression | 8.6 | 7.4 |
| Hypesthesia | 5.3 | 2.0 |
| Respiratory System | ||
| Dyspnea | 10.5 | 7.4 |
| Upper respiratory infection | 8.1 | 10.9 |
| Pneumonia | 5.3 | 3.5 |
| Skin and Appendages | ||
| Sweating | 6.2 | 3.0 |
| Body hair loss | 5.7 | 0.5 |
| Dry skin | 5.3 | 2.5 |
| Rash | 5.3 | 4.0 |
| Special Senses | ||
| Impaired adaptation to dark | 56.9 | 5.4 |
| Chromatopsia | 8.6 | 0.0 |
| Impaired adaptation to light | 7.7 | 1.0 |
| Abnormal vision | 6.2 | 4.5 |
| Urogenital System | ||
| Testicular atrophy | 16.3 | 12.4 |
| Gynecomastia | 10.5 | 11.9 |
| Urinary tract infection | 8.6 | 21.3 |
| Hematuria | 8.1 | 7.9 |
| Urinary tract disorder | 7.2 | 10.4 |
| Nocturia | 6.7 | 6.4 |
The overall incidence of adverse experiences is 99.5% (208/209) for the Nilutamida Lafedar group and 98.5% (199/202) for the placebo group.
Some frequently occurring adverse experiences, for example hot flushes, impotence, and decreased libido, are known to be associated with low serum androgen levels and known to occur with medical or surgical castration alone. Notable was the higher incidence of visual disturbances (variously described as impaired adaptation to darkness, abnormal vision, and colored vision), which led to treatment discontinuation in 1% to 2% of patients.
Interstitial pneumonitis occurred in one ( < 1%) patient receiving Nilutamida Lafedar in combination with surgical castration and in seven patients (3%) receiving Nilutamida Lafedar in combination with leuprolide and one patient receiving placebo in combination with leuprolide. Overall, it has been reported in 2% of patients receiving Nilutamida Lafedar. This included a report of interstitial pneumonitis in 8 of 47 patients (17%) in a small study performed in Japan.
In addition, the following adverse experiences were reported in 2 to 5% of patients treated with Nilutamida Lafedar in combination with leuprolide or orchiectomy.
Body as a Whole: Malaise (2%).
Cardiovascular System: Angina (2%), heart failure (3%), syncope (2%).
Digestive System: Diarrhea (2%), gastrointestinal disorder (2%), gastrointestinal hemorrhage (2%), melena (2%).
Metabolic and Nutritional System: Alcohol intolerance (5%), edema (2%), weight loss (2%).
Musculoskeletal System: Arthritis (2%).
Nervous System: Dry mouth (2%), nervousness (2%), paresthesia (3%).
Respiratory System: Cough increased (2%), interstitial lung disease (2%), lung disorder (4%), rhinitis (2%).
Skin and Appendages: Pruritus (2%).
Special Senses: Cataract (2%), photophobia (2%).
Laboratory Values: Haptoglobin increased (2%), leukopenia (3%), alkaline phosphatase increased (3%), BUN increased (2%), creatinine increased (2%), hyperglycemia (4%).
To report SUSPECTED ADVERSE REACTIONS, contact Concordia Pharmaceuticals Inc. at 1-877370-1142 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Nilutamida Lafedar tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2).
For maximum benefit, Nilutamida Lafedar treatment must begin on the same day as or on the day after surgical castration.
Analysis of blood, urine, and feces samples following a single oral 150-mg dose of [14C]-nilutamide in patients with metastatic prostate cancer showed that the drug is rapidly and completely absorbed and that it yields high and persistent plasma concentrations.
DistributionAfter absorption of the drug, there is a detectable distribution phase. There is moderate binding of the drug to plasma proteins and low binding to erythrocytes. The binding is nonsaturable except in the case of alpha-1-glycoprotein, which makes a minor contribution to the total concentration of proteins in the plasma. The results of binding studies do not indicate any effects that would cause nonlinear pharmacokinetics.
MetabolismThe results of a human metabolism study using 14C-radiolabelled tablets show that nilutamide is extensively metabolized and less than 2% of the drug is excreted unchanged in urine after 5 days. Five metabolites have been isolated from human urine. Two metabolites display an asymmetric center, due to oxidation of a methyl group, resulting in the formation of D-and L-isomers. One of the metabolites was shown, in vitro, to possess 25 to 50% of the pharmacological activity of the parent drug, and the D-isomer of the active metabolite showed equal or greater potency compared to the L-isomer. However, the pharmacokinetics and the pharmacodynamics of the metabolites have not been fully investigated.
EliminationThe majority (62%) of orally administered [14C]-nilutamide is eliminated in the urine during the first 120 hours after a single 150-mg dose. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days. Excretion of radioactivity in urine likely continues beyond 5 days. The mean elimination half-life of nilutamide determined in studies in which subjects received a single dose of 100300 mg ranged from 38.0 to 59.1 hours with most values between 41 and 49 hours. The elimination of at least one metabolite is generally longer than that of unchanged nilutamide (59-126 hours). During multiple dosing of 150 mg nilutamide (given as 3 x 50 mg) twice a day, steady state was reached within 2 to 4 weeks for most patients, and mean steady state AUC0-12 was 110% higher than the AUC0∞obtained from the first 150 mg dose. These data and in vitro metabolism data suggest that, upon multiple dosing, metabolic enzyme inhibition may occur for this drug.
Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese subjects showed that 8 of 47 patients (17%) developed interstitial pneumonitis. Reports of interstitial changes including pulmonary fibrosis that led to hospitalization and death have been reported rarely post-marketing. Symptoms included exertional dyspnea, cough, chest pain, and fever. X-rays showed interstitial or alveolo-interstitial changes, and pulmonary function tests revealed a restrictive pattern with decreased DLco. Most cases occurred within the first 3 months of treatment with Nilutamida Lafedar, and most reversed with discontinuation of therapy. A routine chest X-ray should be performed prior to initiating treatment with Nilutamida Lafedar. Baseline pulmonary function tests may be considered. Patients should be instructed to report any new or worsening shortness of breath that they experience while on Nilutamida Lafedar. If symptoms occur, Nilutamida Lafedar should be immediately discontinued until it can be determined if the symptoms are drug related.
HepatitisRare cases of death or hospitalization due to severe liver injury have been reported post-marketing in association with the use of Nilutamida Lafedar. Hepatotoxicity in these reports generally occurred within the first 3 to 4 months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in 1% of Nilutamida Lafedar patients in controlled clinical trials.
Serum transaminase levels should be measured prior to starting treatment with Nilutamida Lafedar, at regular intervals for the first 4 months of treatment, and periodically thereafter. Liver function tests should also be obtained at the first sign or symptom suggestive of liver dysfunction, e.g. nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, or right upper quadrant tenderness. If at any time, a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, Nilutamida Lafedar should be immediately discontinued with close followup of liver function tests until resolution.
Use In WomenNilutamida Lafedar has no indication for women, and should not be used in this population, particularly for non-serious or non-life threatening conditions.
OtherForeign postmarketing surveillance has revealed isolated cases of aplastic anemia in which a causal relationship with Nilutamida Lafedar could not be ascertained.
PRECAUTIONS General Antiandrogen Withdrawal SyndromePatients whose disease progresses while being treated with an antiandrogen may experience clinical improvement with discontinuation of the antiandrogen.
Carcinogenesis, Mutagenesis, Impairment Of FertilityAdministration of nilutamide to rats for 18 months at doses of 0, 5, 15, or 45 mg/kg/day produced benign Leydig cell tumors in 35% of the high-dose male rats (AUC exposures in high-dose rats were approximately 1 -2 times human AUC exposures with therapeutic doses). The increased incidence of Leydig cell tumors is secondary to elevated luteinizing hormone (LH) concentrations resulting from loss of feedback inhibition at the pituitary. Elevated LH and testosterone concentrations are not observed in castrated men receiving Nilutamida Lafedar. Nilutamide had no effect on the incidence, size, or time of onset of any spontaneous tumor in rats.
Nilutamide displayed no mutagenic effects in a variety of in vitro and in vivo tests (Ames test, mouse micronucleus test, and two chromosomal aberration tests).
In reproduction studies in rats, nilutamide had no effect on the reproductive function of males and females, and no lethal, teratogenic, or growth-suppressive effects on fetuses were found. The maximal dose at which nilutamide did not affect reproductive function in either sex or have an effect on fetuses was estimated to be 45 mg/kg orally (AUC exposures in rats approximately 1-2 times human therapeutic AUC exposures).
PregnancyAnimal reproduction studies have not been conducted with nilutamide. It is also not known whether nilutamide can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Nilutamide should be given to a pregnant woman only if clearly needed.
Pediatric UseSafety and effectiveness in pediatric patients have not been determined.
The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day. Nilutamida Lafedar tablets can be taken with or without food.
